Search Results - therapeutic

27 Results

Sort By:

Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers

Abstract: Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. As a result, mesothelin is an excellent candidate for tumor targeted immunotherapeutics. However, the...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Ira Pastan

Keywords(s): ANTIBODY, Immunotherapy, MESOTHELIN, therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents

Abstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Masanori Onda, Tapan Bera, Mitchell Ho

Keywords(s): ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington

Keywords(s): : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent

Abstract: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Xiu Fen Liu, Tapan Bera, Masanori Onda, Mitchell Ho

Keywords(s): ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain

Abstract: Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types. Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics. Plk1 contains an allosteric domain, known as the polo-box domain (PBD),...

Published: 5/22/2024 | Inventor(s): Terrence Burke, Wen-Jian Qian, Kyung Lee, Jung-Eun Park, James Kelley

Keywords(s): Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer

Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li

Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...

Published: 7/29/2024 | Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan

Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing

Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors

Abstract: Papillomavirus pseudoviruses that comprise the L1/L2 capsid proteins can package a wide variety of non-viral DNA plasmids and deliver the packaged genetic material to cells. This function makes them attractive candidates as targeted gene delivery vehicles. Current methods for the efficient production of papillomavirus pseudoviruses require...

Published: 4/8/2024 | Inventor(s): John Schiller, Carla Correia Cerqueira, Patricia Day, Douglas Lowy, David Fitzgerald

Keywords(s): CANCER, cancer therapeutic, cell-free production, papillomavirus, Schiller, therapeutic, tumor therapy, Vaccine, vectors, virus based gene transfer vectors

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology

Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer

Abstract: Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that playings a critical role in repairing nucleic acid lesions, namely by repairing trapped DNA cleavage complexes. TDP2 repairs topoisomerase (TOP2)-mediated DNA damage induced by chemotherapeutic agents and removes endogenous TOP2-DNA cleavage complexes. Further, TDP2 deficiency potentiates...

Published: 4/8/2024 | Inventor(s): Christophe Marchand, Lin-kun An, Yves Pommier

Keywords(s): CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)

Published: 5/22/2024 | Inventor(s): Terrence Burke, Jung-Eun Park, Wen-Jian Qian, Fa Liu, Kyung Lee

Keywords(s): Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

1 2 3